What is the mechanism of progression with trastuzumab treatment - Escape or resistance?

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 11, 2012, Pages 5915-5916

  Şendur, Mehmet Ali Nahit ^a   Aksoy, Sercan ^b   Özdemir, Nuriye Yildirim ^a   Zengin, Nurullah ^a   Altundag̀, Kadri ^b  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Anti HER2 treatment; Breast cancer; Lapatinib; Trastuzumab

Indexed keywords

EID: 84874040790     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.11.5915     Document Type: Note

References (13)

1. Adams CW, Allison DE, Flagella K, et al (2006). Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunology - Immunotherapy, 55, 717-7.
2. Bailey TA, Luan H, Clubb RJ, et al (2011). Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance. J Carcinogenesis, 10, 8.
3. Baselga J, Bradbury I, Eidtmann H, et al (2012). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, 18, 633-0.
4. Baselga J, Cortés J, Kim SB, et al (2011). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. The New England J Med, 366, 109-9
5. Gianni L, Pienkowski T, Im YH, et al. (2011). Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncology, 13, 25-2
6. Marty M, Cognetti F, Maraninchi D, et al (2005). Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clinical Oncology, 23, 4265-4.
7. Montemurro F, Valabrega G, Aglietta M (2007). Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opinion on Biological Therapy, 7, 257-8.
8. Nahta R, Hung MC, Esteva FJ (2004). The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res, 64, 2343-6.
9. Ross JS, Slodkowska EA, Symmans WF, et al (2009). The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist, 14, 320-8.
10. Slamon DJ, Leyland-Jones B, Shak S, et al (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England J Med, 344, 783-2.
11. Tortora, G (2011). Mechanisms of Resistance to HER2 Target Therapy. J National Cancer Institute, 95-8.
12. Tovey SM, Witton CJ, Bartlett JM, et al (2004). Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast cancer Res, 6, 246-1.
13. Wu Y, Amonkar MM, Sherrill BH, et al (2011). Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Eur Society for Med Oncology, 22, 2582-90.